Trialbee has developed a web based platform and methodology which enable the Novo Nordisk to perform fast and effective patient recruitment to specific clinical trials. Trialbee helps reduce the time required for recruitment resulting in ...
Biogen Idec announced that the US Food and Drug Administration (FDA) has extended its review of a marketing application for the long-lasting recombinant factor IX Fc fusion protein Alprolix for haemophilia B by three months. The company ...
Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of Rixubis, recombinant factor IX for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. ...
Tags: Baxter, European Medicines Agency
Danish pharmaceutical firm Novo Nordisk has received biologics licence application (BLA) approval from the US Food and Drug Administration (FDA) for its recombinant coagulation factor VIII, Novoeight. Novoeight is intended for adults and ...
Tags: Novo Nordisk, Drug
Danish pharmaceutical company Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing approval for its NovoEight (turoctocog alfa), ...
Tags: Novo Nordisk, Novoeight
The Duke of York visited the Churchill Hospital in Oxford during December to commemorate the opening of a new building that includes an integrated Cancer and Haematology Centre and provides a base for many NIHR Oxford Biomedical Research ...
Tags: Duke of York, Churchill Hospital, Oxford
Novo Nordisk is seeking regulatory approval for a recombinant coagulation factor VIII, turoctocog alfa (NN7008), intended for prevention and treatment of bleeding in people with haemophilia A, in the Europe and the US. The filing for ...
Tags: Novo Nordisk, recombinant coagulation factor VIII, haemophilia